108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
一种天然化合物黄芪紫檀烷：理化性质、药理活性、药代动力学和资源开发
Authors Lin Z , Liang M, Zhang X, Cen Z, Kang F, Liang B, Lai Y, Li M, Duan T, Yang J, Liu B
Received 20 January 2025
Accepted for publication 22 April 2025
Published 8 May 2025 Volume 2025:19 Pages 3763—3777
DOI https://doi.org/10.2147/DDDT.S518508
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Manfred Ogris
摘要：
黄芪紫檀烷（Methylnissolin，又称Astrapterocarpan），是一种具有紫檀烷母核结构的异黄酮类化合物。目前，豆科黄芪属植物是黄芪紫檀烷及其苷类衍生物（Methylnissolin-3-O-glucoside）的唯一天然来源。黄芪紫檀烷及其苷类成分可以通过口服吸收入血并发挥抗炎、抗氧化、调节糖脂代谢及抗肿瘤等药理活性，具有广阔的药物开发前景。本文深入探讨了黄芪紫檀烷及其苷类衍生物的理化性质、药理活性、作用机制、药代动力学和毒理学特征，特别对其在体内的代谢反应及代谢产物进行了系统梳理。同时通过分析含有黄芪紫檀烷及其苷类成分较高的黄芪道地产区及提取部位，为药物研发及资源利用提供重要参考依据。